CD4 and neoplasm: Although tumour-infiltrating Tregs were known to be immunosuppressive, distinct from anti-tumour CD4+ Tconvs [67, 74, 75], these early studies raised the question of whether tumour antigen-specific Tregs could potentially acquire an effector phenotype under certain conditions and contribute towards anti-tumour immunity.